BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the US FDA Office of Orphan Products Development (OOPD) has granted orphan drug designation (ODD) to exidavnemab for the treatment ...

Lundbeck has gained orphan drug designation (ODD) from Japan’s Ministry of Health, Labor and Welfare (MHLW) for amlenetug to ...

A live webcast of the fireside chat may be accessed by visiting the Events page of the Company’s website at www.promisneurosciences.com, and will be available for at least 30 days following the event.

Despite recent progress, significant risks remain, leading me to stay on the sidelines regarding investment in Theravance. Explore more details here.

Multiple system atrophy (MSA) is not exactly a household word – a situation that Alterity Therapeutics is seeking to change.

Spinal bulbar muscular atrophy (SBMA) causes a loss of motor neurons in the spinal cord and brainstem. It mainly affects facial and swallowing muscles and the muscles in the arms and legs.

Scientists report results from a promising new approach to treat the rare neurodegenerative disorder. Spinal muscular atrophy (SMA) is a progressive neurodegenerative disorder set in motion before ...

Phase 2 trial shows promising results in slowing disease progression Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) has reported positive Phase 2 trial results for ATH434, its lead candidate for ...

The dynamics of the multiple system atrophy treatment market is anticipated to change during the forecast period as companies across the 7MM are diligently working towards the development of novel ...

The FDA has granted Fast Track Designation to Lundbeck's investigational drug, amlenetug, a potential new treatment option targeting Multiple System Atrophy (MSA). Lundbeck has recently initiated ...